

FOR HEALTHCARE PROFESSIONALS

This GSK promotional program is limited to US healthcare professionals (HCPs) only. Some state laws prohibit pharmaceutical manufacturers from providing meals or limit transfers of value to HCPs. Many employers (eg, hospitals, teaching institutions, government) also restrict what employees may accept from outside parties. Please do not accept any meal that violates the laws of the state(s) in which you are licensed or practice or the rules of your employer. GSK publicly discloses transfers of value as required by law, including the monetary value of meals and related expenses provided to attendees at this program.

It's Time to Rethink Management of COPD for Patients With an Eosinophilic Phenotype

Nucala 
(mepolizumab)
Injection 100 mg/mL

NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.



Warren Clifford Botnick, MD



Where

Rock'n Dough Pizza & Brewery
16 Jackson Walk Plaza
Jackson, Tennessee 38301
(731) 300-0404



When

Thursday, August 14, 2025
6:00 PM - CST



To register for this program,
scan the QR code or visit the
following link:

<https://myattendeeresource.com/gsk/250814-gsk-109992>

For Questions, Contact Your GSK Representative

BRENNAN CONDO
robert.b.condo@gsk.com
+19018700821

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). Discontinue if a hypersensitivity reaction occurs.

Please see additional Important Safety Information on reverse side.

Please see accompanying full **Prescribing Information**, including **Patient Information**, for NUCALA.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Acute Symptoms of Asthma or COPD or Acute Deteriorating Disease

NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD, or acute bronchospasm.

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 5\%$) were back pain, diarrhea, and cough.

USE IN SPECIFIC POPULATIONS

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

Please see additional Important Safety Information on reverse side.

Please see accompanying full **Prescribing Information, including **Patient Information**, for NUCALA.**

Trademarks are owned by or licensed to the GSK group of companies.

©2025 GSK or licensor.
PMUS-MPLLBND250022 May 2025
Produced in USA.

